In addition to TMB, TILs, and HLA, other potential biomarkers to consider for patient stratification include LAG-3, TIM-3, and circulating tumor DNA, which may provide real-time insights into disease progression and treatment response. This evidence concerns the gene HAVCR2 and neoplasm.